September 08, 2021
The Office of NIH History and Stetten Museum this month is honoring one of the forerunners to Rocky Mountain Laboratories – the Schoolhouse Lab at Canyon Creek, just west of Hamilton, Montana – where 100 years ago scientists worked to develop a vaccine against Rocky Mountain spotted fever.
August 27, 2021
Mice infected during pregnancy generated an immune response in the gut that protected the mother and imprinted that protective response in the developing offspring -- but the response also could make offspring more susceptible to inflammation.
August 23, 2021
For 30 years a group at NIAID’s Rocky Mountain Laboratories worked to define the structure of an infectious prion protein. Last winter, during a pandemic and working 2,000 miles from collaborators, they finished. Or is this a new beginning?
August 20, 2021
World Mosquito Day, recognized each year on August 20, marks the anniversary of the discovery that mosquitoes transmit the parasite that causes malaria. Today, more than 120 years later, mosquito-borne diseases are still both widespread and difficult to treat.
August 20, 2021
On World Mosquito Day, two NIAID scientists describe their research.
August 18, 2021
As the global COVID-19 pandemic continues, safe and effective vaccines are playing a pivotal role in preventing severe disease and death and limiting the spread of SARS-CoV-2, the virus that causes COVID-19. The urgency of the COVID-19 pandemic necessitated rapid vaccine development and testing. Fortunately, NIAID’s decades-long support and conduct of coronavirus and vaccine research laid the groundwork for helping to develop a safe and effective COVID-19 vaccine in record speed.
July 14, 2021
A study funded by the National Institute of Allergy and Infectious Diseases contributes to the evidence for a new guideline on how to induce remission and treat relapse of a rare, severe autoimmune disease called ANCA-associated vasculitis.
June 22, 2021
The idea that microscopic organisms can successfully live inside the human body is not a new one. Some of the first microbiological studies, dating back about 350 years, found that microscopic organisms, such as bacteria and yeast, inhabit the human body. To get a better sense of the current state of microbiome research, the NIAID Now Blog checked in with Dr. Ryan Ranallo - a NIAID Program Officer and Co-Chair for the Trans-NIH Microbiome Working Group.
June 17, 2021
Nearly a third of infants who are hospitalized with a severe form of a common childhood lung infection called bronchiolitis develop asthma a few years later. However, clinicians have been unable to predict which infants with severe bronchiolitis are at high risk for developing asthma and to understand why. Now, a NIAID-funded study published in the journal Nature Communications has taken a step toward accomplishing this.
May 18, 2021
While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.
May 06, 2021
Scientists at NIAID’s Vaccine Research Center and their NIAID-supported colleagues at the University of Washington School of Medicine used tiny nanoparticles to make a huge leap towards the goal of a universal flu vaccine.
April 01, 2021
Single-dose experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected lungs and nasal regions from SARS-CoV-2 infection.
March 24, 2021
On World TB Day, the National Institute of Allergy and Infectious Diseases (NIAID) joins the World Health Organization and others in acknowledging the need for continued, concerted efforts to combat tuberculosis.
March 12, 2021
NIH’s Dr. Carl Dieffenbach joined HIV.gov for a conversation about the latest HIV prevention and treatment research presented there.
March 09, 2021
NIH’s Dr. Carl Dieffenbach shared highlights from HIV research presented at the 2021 virtual Conference on Retroviruses and Opportunistic Infections.
February 09, 2021
NIAID-funded research has expanded the toolbox of medical countermeasures available in case a catastrophic event exposes people to high doses of radiation.
January 29, 2021
An overview of Neglected Tropical Diseases Day and NIAID's long-standing research program devoted to better understanding, treating, and preventing NTDs.
January 14, 2021
By studying the rare disease APECED, NIAID researchers and colleagues uncovered an unexpected immune mechanism that promotes susceptibility to fungal infections of the mucous membranes. Their findings suggest potential therapies for people with APECED and pave the way for work to investigate these tissue-specific immune responses in other diseases.
November 06, 2020
Winners of the 2020 Nobel Prize in Physiology or Medicine included an NIH scientist and a long-time NIAID grantee.
October 23, 2020
A NIAID-sponsored study has shown that short-course antibiotic treatment is superior to standard treatment of community-acquired pneumonia in children.
October 19, 2020
New NIAID-funded research answers longstanding questions about key steps in HIV life cycle.
October 06, 2020
In a study by the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), researchers investigated the possibility that SARS-CoV-2, the virus that causes COVID-19, could be transmitted to infants through breast milk from mothers who have been infected with SARS-CoV-2. The study enrolled 18 breastfeeding mothers who tested positive for SARS-CoV-2.
September 24, 2020
NIH has awarded approximately $10 million to support implementation science research which aims to reduce new HIV diagnoses in the United States.
September 22, 2020
NIAID Now speaks to Dr. Remais about his research and why a better understanding of the epidemiology of Valley Fever is important.
September 03, 2020
During pregnancy, the mother’s immune system accepts, or tolerates, the presence of the fetus rather than rejecting it as something foreign in the body. This immune tolerance, which dampens the normal maternal immune response, must be carefully balanced with the need to prevent infections from spreading to the placenta and then to the developing fetus.